查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2002666

口服固体製剂契约製造市场：依剂型、治疗领域、研发阶段、应用及最终用户划分－2026-2032年全球市场预测

Oral Solid Dosage Contract Manufacturing Market by Form Type, Therapeutic Area, Stage, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年口服固体製剂的契约製造市场价值为 481 亿美元，预计到 2026 年将成长至 523.9 亿美元，年复合成长率为 9.13%，到 2032 年将达到 887 亿美元。

主要市场统计数据
基准年 2025 481亿美元
预计年份：2026年 523.9亿美元
预测年份 2032 887亿美元
复合年增长率 (%) 9.13%

简明扼要、全面介绍当前影响口服固体製剂契约製造的趋势及其对相关人员的策略意义。

口服固体製剂契约製造产业处于医药创新、复杂供应链和严格管理体制的交汇点，要求相关人员在敏捷性和卓越品质之间取得平衡。本执行摘要概述了影响生产力计画、製剂策略和合作伙伴选择的结构性因素，重点关注上市速度与长期业务永续营运之间的竞争关係，从而整体情况了该行业。随着开发平臺的扩展和客户需求的多样化，契约製造製造商正从单纯的生产合作伙伴转变为提供製剂专业知识、法规知识和生命週期管理支援的策略伙伴。

分析技术、法规和供应链的变革性变化，这些变化正在重新定义契约製造中的生产能力、品质期望和伙伴关係模式。

口服固体製剂的契约製造产业正经历一系列变革，这些变革的驱动力来自技术进步、监管要求以及不断变化的客户需求。连续生产和先进的製程控制系统正从试点阶段走向成熟，最终成为检验的生产路线，从而提高了生产效率并加强了对关键品质属性的控制。同时，生产营运的数位化，包括电子批次记录、预测性维护和进阶分析，正在重塑产能监控、偏差管理和监管证据收集的方式。这些技术进步正在催生新的伙伴关係模式，製造商不再仅仅提供单一批次的生产服务，而是提供整合的开发和规模化服务。

评估 2025 年美国关税政策变化对采购、成本结构、供应链韧性和策略采购选择的累积影响。

美国推出的2025年关税政策对口服固体製剂契约製造的采购选择、单位成本结构和紧急时应对计画产生了多方面的影响。关税调整影响了中间辅料、活性药物成分和某些资本设备的进口成本竞争力，促使许多製造商及其客户重新评估供应商选择和库存策略。一些企业正在采取即时措施来降低跨境成本波动带来的风险，例如采购管道多元化、建立关键原材料的库存缓衝以及评估近岸外包和回岸外包的替代方案。然而，这些战术性措施需要在营运成本密集度和供应链柔软性之间做出权衡。

细分市场的洞察揭示了剂型、治疗领域、应用、开发阶段和客户类型如何影响契约製造业务的服务需求。

了解细分市场的发展趋势对于理解口服固体製剂契约製造的需求驱动因素和产能要求至关重要。当剂型是首要考虑因素时，与片剂相比，胶囊在供应链和生产设施方面有着独特的要求。胶囊分为硬胶囊和软胶囊；颗粒剂需要考虑速释和缓释；丸剂需要包衣丸剂和多颗粒製剂方面的专业知识；片剂则根据是否包衣而采用不同的生产方法。这些剂型特有的因素决定了资本投资、分析测试的范围和稳定性测试方案的复杂性，以及哪些供应商适合进行研发工作，哪些供应商更适合大规模商业化生产营运。

区域战略展望：美洲、欧洲、中东和非洲以及亚太地区的趋势如何重塑製造地、物流和监管应对措施

区域趋势差异显着，影响製造商在製造地、监管策略和物流方面的策略选择。在美洲，製造商受益接近性大规模商业市场和响应迅速的分销网络，同时也面临着严格的监管审查和激烈的竞争压力，这些压力要求某些产品类型的生产本地化。该地区通常是后期商业供应链和项目的首选之地，因为在这些项目中，产品上市时间和快速补货能力至关重要，从而支持那些检验的大规模生产能力和先进品质系统的商业模式。

竞争资讯概述了领先的契约製造的策略重点、产能投资和伙伴关係方式。

领先的契约製造透过整合先进的技术能力、一体化的开发服务以及卓越的合规记录来脱颖而出。顶级供应商会选择性地投资于检验于多种固态製剂形式的灵活生产平台，同时维持严格的资料完整性和品质保证系统。他们通常会将生产能力投资与配方优化、分析方法开发和稳定性测试等辅助服务相结合，使客户能够顺利地从临床批次过渡到商业化生产，而无需重复的供应商交接。

为行业领导者提供切实可行的建议，以增强韧性、提高效率、抓住新机会，并使其营运适应不断变化的客户和监管要求。

行业领导者可以透过制定一系列重点明确的营运和商业优先事项，将洞察转化为实际行动。首先，投资于模组化、灵活的生产平台，该平台支援胶囊、颗粒、丸剂和片剂生产之间的快速切换，同时保持检验的品管。这种方法降低了进入不同项目的门槛，并加快了对不断变化的客户需求的反应速度。同时，加强製剂开发和分析服务，以应对复杂的治疗领域，从低剂量中枢神经系统 (CNS) 产品到需要特殊隔离和稳定性通讯协定的肿瘤製剂。这些能力可以缩短规模化生产时间，并增强您作为长期伙伴关係伙伴的吸引力。

一套完善的调查方法，详细说明了主要和次要数据的收集、专家检验、品管以及用于确保严谨见解和可重复性的分析框架。

本执行摘要的研究途径整合了多个资料流和检验通讯协定，以确保分析的严谨性和可操作性。主要研究包括对契约製造及其基本客群中的技术负责人、品质主管、供应链经理和业务拓展主管进行结构化访谈。这些访谈提供了关于产能投资、商业重点以及监管和贸易趋势对营运影响的第一手观点。次要研究利用了公开的监管指南、专利申请、临床试验註册资讯和开放原始码企业资讯披露，以阐明观察到的趋势并识别产能部署的变化。

全面概述了口服固体製剂生产中面临的战略挑战、风险因素以及投资和营运调整的优先领域。

本概要重点阐述了固态製剂契约製造领域相关人员面临的几项关键通用挑战。技术差异化、营运柔软性和供应链韧性将成为决定哪些供应商能够赢得策略合约以及哪些客户能够确保可靠供应的关键因素。随着连续生产、数位化品质系统和先进製剂开发能力从早期采用者走向行业标准，契约製造製造商的价值提案将取决于其能否将这些能力整合到一个统一的、面向客户的服务模式中。监管对可追溯性和即时品质保证的要求进一步提升了这项策略需求，因此必须投资于能够支援合规性和营运改善的数据系统。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：口服固体製剂的契约製造市场（以剂型划分）

  • 胶囊
    • 硬明胶
    • 软明胶
  • 颗粒
    • 立即发布
    • 缓释
  • 颗粒
    • 包衣颗粒
    • 多颗粒配方
  • 药片
    • 包衣片
    • 无涂层

第九章：口服固体製剂的契约製造市场：依治疗领域划分

  • 感染疾病物
    • 抗生素
    • 抗病毒药物
  • 循环系统
    • 高血脂症
    • 高血压
  • 中枢神经系统
    • 忧郁症
    • 癫痫
  • 消化器官系统
    • 抑酸剂
    • 胃肠动力刺激剂
  • 肿瘤学
    • 血液疾病
    • 固态肿瘤

第十章：口服固体製剂的契约製造市场：依阶段划分

  • 临床试验
  • 商业的

第十一章：口服固体製剂的契约製造市场：依应用领域划分

  • 非处方药
  • 处方药

第十二章：口服固体製剂的契约製造市场：依最终用户划分

  • 生物技术
  • 营养保健品
  • 製药

第十三章：口服固体製剂契约製造市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：口服固体製剂的契约製造市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：口服固体製剂契约製造市场：依国家口服固体製剂

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国口服固体製剂契约製造市场

第十七章：中国口服固体製剂契约製造市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Ajinomoto Bio-Pharma Services, LLC
  • Almac Group Ltd.
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • CordenPharma International GmbH
  • Curia Global, Inc.
  • Evonik Industries AG
  • Fareva SA
  • Hetero Drugs Limited
  • Jubilant Pharmova Limited
  • Lonza Group AG
  • PCI Pharma Services, Inc.
  • Piramal Pharma Limited
  • Recipharm AB
  • Siegfried Holding AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-0D217D5AE60A

The Oral Solid Dosage Contract Manufacturing Market was valued at USD 48.10 billion in 2025 and is projected to grow to USD 52.39 billion in 2026, with a CAGR of 9.13%, reaching USD 88.70 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 48.10 billion
Estimated Year [2026] USD 52.39 billion
Forecast Year [2032] USD 88.70 billion
CAGR (%) 9.13%

A concise but comprehensive introduction that frames the current dynamics shaping oral solid dosage contract manufacturing and strategic relevance to stakeholders

The oral solid dosage contract manufacturing sector sits at the intersection of pharmaceutical innovation, complex supply chains, and stringent regulatory regimes, requiring stakeholders to balance agility with uncompromising quality. This executive summary introduces the landscape by outlining the structural drivers that dictate capacity planning, formulation strategy, and partner selection, and by framing the competitive tensions between speed-to-market and long-term operational resilience. As development pipelines broaden and customer needs diversify, contract manufacturers are transitioning from pure production partners to strategic collaborators who contribute formulation expertise, regulatory know-how, and lifecycle management support.

Understanding the forces at play requires a clear view of how product form and therapeutic focus inform manufacturing complexity, how clinical and commercial stages alter demand patterns, and how customer types-ranging from biotechnology innovators to established pharmaceutical companies and nutraceutical producers-shape service expectations. This introduction establishes the analytical lens used throughout the report: one that integrates technical capability assessment with commercial strategy and supply chain risk management. It also highlights the imperative for decision-makers to adopt an evidence-based approach to outsourcing that weighs the benefits of specialization against the vulnerabilities introduced by concentrated supplier networks and evolving trade policies. The remainder of this executive summary translates these observations into actionable insights for procurement, operations, regulatory affairs, and business development leaders.

An analysis of transformative technological, regulatory, and supply chain shifts redefining capacity, quality expectations, and partnership models in contract manufacturing

The contract manufacturing landscape for oral solid dosage forms is undergoing a series of transformative shifts driven by converging technological advances, regulatory expectations, and changing client demands. Continuous manufacturing and advanced process control systems are maturing from pilot demonstrations into validated production routes, enabling improved throughput and tighter control of critical quality attributes. At the same time, digitalization of manufacturing operations-covering electronic batch records, predictive maintenance, and advanced analytics-reshapes how capacity is monitored, deviations are managed, and regulatory evidence is compiled. These technology-enabled improvements are leading to new partnership models in which manufacturers offer integrated development and scale-up services rather than discrete batch production slots.

Regulatory frameworks are also evolving, with agencies prioritizing real-time product quality assurance and lifecycle data that demonstrate robustness and traceability. This regulatory emphasis increases the value of integrated data ecosystems and strengthens the negotiating position of manufacturers that can demonstrate end-to-end quality controls. Moreover, the rise of complex formulations and multiparticulate technologies adds technical differentiation to service offerings, pushing contract manufacturers to invest selectively in specialized capabilities. Concurrently, customer expectations are shifting: biotechnology firms seek nimble, development-focused partners; large pharmaceutical companies prioritize long-term, compliant suppliers with proven global distribution capabilities; and nutraceutical customers emphasize cost efficiency and rapid market access. The interaction of these factors is prompting a redefinition of what it means to be a strategic contract manufacturing partner and is accelerating consolidation, capability specialization, and collaborative commercialization models.

An assessment of the cumulative effects of United States tariff policy changes in 2025 on sourcing, cost structures, supply chain resilience, and strategic sourcing choices

The 2025 tariff environment introduced by the United States has produced layered implications across sourcing choices, unit cost structures, and contingency planning for contract manufacturing of oral solid dosage forms. Tariff adjustments have affected the cost competitiveness of importing intermediate excipients, active pharmaceutical ingredients, and certain capital equipment, prompting many manufacturers and their customers to reassess supplier footprints and inventory strategies. For some organizations, the immediate response has been to diversify procurement channels, build inventory cushions for critical raw materials, and evaluate nearshoring or reshoring alternatives to reduce exposure to cross-border cost volatility. These tactical moves, however, entail trade-offs between working capital intensity and supply chain flexibility.

Beyond procurement, tariff-induced input cost variability is influencing upstream decisions in formulation development and process selection. Teams are increasingly favoring formulations and excipient sets that minimize exposure to tariff-sensitive components or that permit substitution without compromising stability or performance. In parallel, contract manufacturers are investing in supply chain mapping and dual-sourcing strategies to mitigate single-point-of-failure risks. The tariffs also elevate the strategic importance of logistics optimization, classification accuracy, and free trade zone utilization as levers to manage landed costs. Looking forward, operational resilience will depend less on single cost advantages and more on the ability to integrate procurement agility, regulatory compliance for material substitutions, and transparent supplier relationships into a coherent risk-mitigation posture.

Segment-driven insights revealing how form, therapeutic focus, application, development stage, and customer type influence service demands across contract manufacturing operations

Segment-level dynamics are central to understanding demand drivers and capability requirements across oral solid dosage contract manufacturing. When form type considerations are front and center, capsules present distinct supply chain and tooling requirements compared to tablets; capsules can be segmented into hard gelatin and soft gelatin variants, while granules carry immediate release and modified release considerations, pellets require coated pellet or multiparticulate expertise, and tablets demand differentiated approaches for coated and uncoated configurations. These form-specific factors determine equipment investments, analytical testing scope, and stability program complexity, and they influence which providers are suited to development versus high-volume commercial work.

Therapeutic area focus further shapes service profiles, with anti-infective programs spanning antibiotics and antivirals that often emphasize rapid scale-up and stringent potency controls, and cardiovascular portfolios addressing hyperlipidemia and hypertension with long-term release and high-stability demands. Central nervous system therapies bring requirements for low-dose precision and controlled-release depression or epilepsy formulations, while gastrointestinal treatments such as acid reducers and prokinetics impose unique dissolution and biopharmaceutic considerations. Oncology work, whether hematological or solid tumor-directed, requires specialized containment, chain-of-custody processes, and patient-safety-focused quality systems. Application orientation-over-the-counter versus prescription-affects regulatory pathways, labeling, and shelf-life expectations, and the distinction between clinical trial-stage and commercial-stage projects determines the balance between flexibility and validated repeatability. Finally, customer type influences engagement models: biotechnology companies often require bespoke development support and agility, nutraceutical clients prioritize cost-efficient production and rapid time-to-shelf, and pharmaceutical customers emphasize long-term supply reliability and global regulatory harmonization. Taken together, these segmentation dimensions provide a framework for aligning technical investments, commercial positioning, and partnership design to client-specific needs.

Regional strategic outlook describing how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics are reshaping manufacturing footprints, logistics, and regulatory navigation

Regional dynamics vary considerably and shape strategic choices for manufacturing footprint, regulatory strategy, and logistics. In the Americas, manufacturers benefit from proximity to large commercial markets and rapid-response distribution networks, but they also face stringent regulatory scrutiny and competitive pressure to localize production for certain product classes. This region is often chosen for late-stage commercial supply and for programs where time-to-market and rapid replenishment capabilities are critical, and it supports models that emphasize validated large-scale capacity and advanced quality systems.

Europe, Middle East & Africa present a multifaceted environment in which regulatory heterogeneity and fragmented pricing landscapes require sophisticated regulatory intelligence and flexible distribution planning. Manufacturers operating in this region must navigate diverse approval pathways, varying regulatory timelines, and regional trade agreements that influence where clinical and commercial batches are produced. Capability investments here often include modular facilities and robust pharmacovigilance infrastructures to support multinational launches and post-approval commitments.

Asia-Pacific remains a strategic hub for both development-stage work and volume manufacturing, offering extensive capabilities in formulation development, cost-competitive production, and rapidly expanding analytical and regulatory expertise. However, companies in this region must balance cost advantages with growing expectations around quality assurance, data integrity, and compliance with international regulatory standards. Supply chain resilience considerations, including port capacities and geopolitical risks, play a prominent role in regional sourcing decisions and in choices about inventory positioning for global programs.

Competitive intelligence summarizing the strategic priorities, capability investments, and partnership approaches that distinguish leading contract manufacturing organizations

Leading contract manufacturers distinguish themselves through a combination of deep technical capabilities, integrated development services, and demonstrated regulatory track records. Top-tier providers invest selectively in flexible production platforms that can be validated across a range of solid dosage forms while maintaining rigorous data integrity and quality assurance systems. They commonly pair capacity investments with adjacent services such as formulation optimization, analytical method development, and stability sciences, enabling clients to transition smoothly from clinical batches to commercial throughput without redundant vendor handoffs.

Another characteristic of high-performing firms is a clear articulation of partnership models that align incentives with client success. This includes transparent cost structures, shared risk arrangements for scale-up, and value-added services such as regulatory dossier support and serialization readiness. Investments in digital operations-real-time batch analytics, integrated quality management systems, and advanced supply chain visibility tools-also segregate leaders from commodity providers. Additionally, firms that cultivate robust supplier ecosystems for excipients, packaging, and specialized tooling are better positioned to manage disruptions and offer reliable lead times. Strategic M&A and alliance activity continue to be vehicles for capability expansion, but the most consequential competitive differentiators remain the ability to deliver predictable quality at scale, to innovate around formulation challenges, and to provide consultative support across product lifecycles.

Actionable recommendations for industry leaders to accelerate resilience, drive efficiency, capture new opportunities, and align operations with evolving customer and regulatory needs

Industry leaders can purposefully translate insight into action by adopting a set of targeted operational and commercial priorities. First, invest in modular, flexible manufacturing platforms that support rapid changeover between capsules, granules, pellets, and tablet production while preserving validated quality controls; this approach lowers barrier-to-entry for diverse programs and accelerates response to shifting client pipelines. Concurrently, strengthen formulation and analytical services to support complex therapeutic areas, from low-dose CNS products to oncology formulations requiring specialized containment and stability protocols. These capabilities reduce time-to-scale and increase the attractiveness of a provider for long-term partnerships.

Second, embed supply chain resilience into procurement and planning by instituting dual-sourcing strategies for critical excipients and leveraging near-term inventory strategies for tariff-sensitive inputs. Augment this with advanced procurement analytics and supplier performance monitoring to detect and remediate vulnerabilities early. Third, prioritize regulatory and data integrity investments that facilitate multinational submissions and real-time quality monitoring, including expanded capabilities for electronic batch records, serialization, and regulatory dossier compilation. Fourth, refine commercial offerings to include outcome-based partnership models and bundled development-to-commercial transition services that align incentives and reduce client friction. Finally, cultivate a digital transformation roadmap that links production analytics, predictive maintenance, and quality metrics to executive dashboards; this enables faster decision cycles, clearer capacity signaling, and demonstrable compliance during audits.

Robust research methodology detailing primary and secondary data collection, expert validation, quality controls, and analytical frameworks used to ensure rigorous insights and reproducibility

The research approach underpinning this executive summary integrates multiple data streams and validation protocols to ensure analytical rigor and practical relevance. Primary research included structured interviews with technical leaders, quality heads, supply chain managers, and business development executives across contract manufacturers and their customer base. These discussions provided first-hand perspectives on capability investments, commercial priorities, and the operational impacts of regulatory and trade developments. Secondary research drew on public regulatory guidance, patent filings, clinical trial registries, and open-source corporate disclosures to contextualize observed trends and identify shifts in capability footprints.

Data synthesis employed triangulation techniques that cross-checked qualitative insights with documented regulatory actions and observed capacity investments. Analytical frameworks included capability mapping, supply chain vulnerability assessment, and partner archetype development, which together enabled the translation of disparate signals into coherent strategic implications. Quality controls involved peer review by subject-matter experts, methodology audits to verify reproducibility of findings, and sensitivity checks to assess the robustness of conclusions against alternative interpretations. Throughout the research process, emphasis was placed on producing actionable intelligence that reflects operational realities and regulatory constraints while maintaining transparency about data sources and the inferential steps taken to derive recommendations.

Concluding synthesis that crystallizes strategic imperatives, risk considerations, and priority areas for investment and operational adaptation in oral solid dosage manufacturing

This executive synthesis highlights several convergent imperatives for stakeholders in oral solid dosage contract manufacturing. Technical differentiation, operational flexibility, and supply chain resilience will increasingly determine which providers win strategic engagements and which clients secure dependable supply. As continuous manufacturing, digital quality systems, and advanced formulation capabilities migrate from early adopters to industry norms, the value proposition of contract manufacturers will rest on the ability to integrate these capabilities into coherent, client-facing service models. Regulatory demands for traceability and real-time quality assurance add another layer of strategic necessity, requiring investment in data systems that support both compliance and operational improvement.

For decision-makers, the path forward requires balancing selective capital allocation with partnership innovation. Investing in modular production and adjacent development services builds optionality, while enhanced procurement strategies and geographic diversification mitigate tariff and logistics risks. Ultimately, organizations that combine technical excellence with consultative engagement-helping clients translate formulation science into scalable, regulatorily defensible production-will be best positioned to capture long-term partnerships. The insights in this summary aim to inform pragmatic next steps across procurement, operations, regulatory affairs, and business development, offering a roadmap for converting structural trends into competitive advantage and operational resilience.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Solid Dosage Contract Manufacturing Market, by Form Type

  • 8.1. Capsules
    • 8.1.1. Hard Gelatin
    • 8.1.2. Soft Gelatin
  • 8.2. Granules
    • 8.2.1. Immediate Release
    • 8.2.2. Modified Release
  • 8.3. Pellets
    • 8.3.1. Coated Pellets
    • 8.3.2. Multiparticulate
  • 8.4. Tablets
    • 8.4.1. Coated
    • 8.4.2. Uncoated

9. Oral Solid Dosage Contract Manufacturing Market, by Therapeutic Area

  • 9.1. Anti Infectives
    • 9.1.1. Antibiotics
    • 9.1.2. Antivirals
  • 9.2. Cardiovascular
    • 9.2.1. Hyperlipidemia
    • 9.2.2. Hypertension
  • 9.3. Central Nervous System
    • 9.3.1. Depression
    • 9.3.2. Epilepsy
  • 9.4. Gastrointestinal
    • 9.4.1. Acid Reducers
    • 9.4.2. Prokinetics
  • 9.5. Oncology
    • 9.5.1. Hematological
    • 9.5.2. Solid Tumor

10. Oral Solid Dosage Contract Manufacturing Market, by Stage

  • 10.1. Clinical Trial
  • 10.2. Commercial

11. Oral Solid Dosage Contract Manufacturing Market, by Application

  • 11.1. Over The Counter
  • 11.2. Prescription Drugs

12. Oral Solid Dosage Contract Manufacturing Market, by End User

  • 12.1. Biotechnology
  • 12.2. Nutraceutical
  • 12.3. Pharmaceutical

13. Oral Solid Dosage Contract Manufacturing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Oral Solid Dosage Contract Manufacturing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oral Solid Dosage Contract Manufacturing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Oral Solid Dosage Contract Manufacturing Market

17. China Oral Solid Dosage Contract Manufacturing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Ajinomoto Bio-Pharma Services, LLC
  • 18.6. Almac Group Ltd.
  • 18.7. Aurobindo Pharma Limited
  • 18.8. Boehringer Ingelheim International GmbH
  • 18.9. Catalent, Inc.
  • 18.10. CordenPharma International GmbH
  • 18.11. Curia Global, Inc.
  • 18.12. Evonik Industries AG
  • 18.13. Fareva SA
  • 18.14. Hetero Drugs Limited
  • 18.15. Jubilant Pharmova Limited
  • 18.16. Lonza Group AG
  • 18.17. PCI Pharma Services, Inc.
  • 18.18. Piramal Pharma Limited
  • 18.19. Recipharm AB
  • 18.20. Siegfried Holding AG
  • 18.21. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HARD GELATIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HARD GELATIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HARD GELATIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOFT GELATIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOFT GELATIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOFT GELATIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MODIFIED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MODIFIED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MODIFIED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED PELLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED PELLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED PELLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPARTICULATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPARTICULATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPARTICULATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY UNCOATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY UNCOATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY UNCOATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERLIPIDEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERLIPIDEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DEPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DEPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ACID REDUCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ACID REDUCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ACID REDUCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROKINETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROKINETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROKINETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY NUTRACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY NUTRACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY NUTRACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 258. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 259. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 260. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 261. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 262. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 263. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 264. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 265. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 266. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 268. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANU